Libris Innovations Appoints Ramani Varanasi as CEO to Drive Growth

Libris Innovations has announced the appointment of Ramani Varanasi as its new Chief Executive Officer, effective January 29, 2026. This strategic move aims to enhance the organization’s efforts in fostering new ventures that emerge from the Indiana Biosciences Research Institute (IBRI) and its partner innovations.

Leadership with Vision

In her new role, Varanasi will focus on providing advisory services to early-stage biotechnology companies, helping them secure the necessary capital and talent for growth. Her appointment signifies IBRI’s commitment to bridging the gap between translational research and the establishment of viable companies, ultimately leading to innovative therapies for patients.

“Libris Innovations builds on the strong research engine the IBRI has established, with a clear focus on translating that work into new companies and, ultimately, therapies for patients,” Varanasi stated. She emphasized the importance of launching new ventures to strengthen the biotech ecosystem in Indianapolis and beyond.

With over three decades of experience in the biopharmaceutical sector, Varanasi has a diverse background that includes substantial roles in both large and small organizations. Her previous position as Executive-in-Residence at University of California at San Francisco Innovation Ventures involved working closely with innovators and early-stage companies to facilitate venture creation and commercialization.

Driving Innovation in Biotechnology

Alan Palkowitz, PhD, President and CEO of IBRI, highlighted the significance of Varanasi’s appointment, noting, “Her leadership and experience will be instrumental in accelerating the translation of research into companies that deliver meaningful benefits for patients in need.” This alignment of expertise and vision positions Libris Innovations to thrive in a rapidly evolving biotechnology landscape.

Under Varanasi’s leadership, Libris Innovations aims to oversee the formation and growth of ventures that stem from IBRI and partner innovation. The organization provides strategic guidance and support to early-stage biotechnology enterprises, enhancing their ability to attract essential resources for success.

The IBRI itself is dedicated to advancing life sciences, striving to eliminate diseases and improve human health. By connecting early-stage biotech companies with academic researchers and leveraging the resources of industry leaders, investors, and philanthropic partners, the institute is reshaping the approach to drug discovery and development.

IBRI’s model promotes a collaborative environment that nurtures early-stage companies with investment, talent, and operational support. This approach not only accelerates drug discovery but also fosters workforce development, ensuring that the scientific advancements benefit patients directly.

As Varanasi steps into her new role, she will lead efforts to translate promising scientific discoveries into tangible medical innovations. Her leadership is expected to play a crucial role in driving forward the mission of Libris Innovations and the broader goals of IBRI.

With a focus on providing clear pathways from research to clinical trials, the IBRI is committed to pursuing breakthroughs that could transform lives. The organization’s innovative financing model ensures that when discoveries are ready for clinical trials, they can be effectively commercialized, creating revenue and opportunities for further research.

As Libris Innovations embarks on this new chapter under Varanasi’s guidance, the impact on the biotechnology landscape in Indianapolis and beyond is poised to be significant. Her experience and vision are expected to catalyze the growth of new companies, ultimately leading to advancements in healthcare and patient outcomes.